F M Investments LLC Invests $2.95 Million in Insmed Incorporated (NASDAQ:INSM)

F M Investments LLC acquired a new stake in Insmed Incorporated (NASDAQ:INSM - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 42,793 shares of the biopharmaceutical company's stock, valued at approximately $2,954,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in INSM. Vanguard Group Inc. boosted its holdings in shares of Insmed by 6.3% during the 4th quarter. Vanguard Group Inc. now owns 18,218,973 shares of the biopharmaceutical company's stock worth $1,257,838,000 after buying an additional 1,075,796 shares during the period. Geode Capital Management LLC lifted its position in Insmed by 7.2% during the 4th quarter. Geode Capital Management LLC now owns 4,087,143 shares of the biopharmaceutical company's stock worth $282,243,000 after acquiring an additional 273,759 shares during the last quarter. Artisan Partners Limited Partnership boosted its holdings in Insmed by 8.4% during the fourth quarter. Artisan Partners Limited Partnership now owns 3,126,339 shares of the biopharmaceutical company's stock valued at $215,842,000 after acquiring an additional 242,242 shares during the period. FIL Ltd grew its position in shares of Insmed by 8.1% in the fourth quarter. FIL Ltd now owns 2,638,160 shares of the biopharmaceutical company's stock valued at $182,139,000 after purchasing an additional 198,412 shares during the last quarter. Finally, William Blair Investment Management LLC increased its stake in shares of Insmed by 0.5% in the fourth quarter. William Blair Investment Management LLC now owns 2,433,443 shares of the biopharmaceutical company's stock worth $168,005,000 after purchasing an additional 12,535 shares during the period.

Remove Ads

Analyst Upgrades and Downgrades

INSM has been the topic of a number of research analyst reports. JPMorgan Chase & Co. raised their target price on Insmed from $83.00 to $92.00 and gave the company an "overweight" rating in a report on Friday, February 7th. Guggenheim reaffirmed a "buy" rating and set a $101.00 target price on shares of Insmed in a research report on Tuesday, February 25th. Bank of America increased their price target on shares of Insmed from $92.00 to $96.00 and gave the company a "buy" rating in a report on Thursday, March 20th. HC Wainwright reiterated a "buy" rating and issued a $90.00 target price on shares of Insmed in a research note on Friday, February 21st. Finally, Morgan Stanley raised their price objective on Insmed from $85.00 to $90.00 and gave the stock an "overweight" rating in a research report on Thursday, February 6th. One research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $94.00.

Insmed Trading Up 3.6 %

INSM stock traded up $2.46 during midday trading on Monday, reaching $71.03. The stock had a trading volume of 2,386,043 shares, compared to its average volume of 2,275,888. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. Insmed Incorporated has a twelve month low of $21.92 and a twelve month high of $84.91. The firm has a market cap of $12.91 billion, a price-to-earnings ratio of -12.71 and a beta of 1.07. The business has a fifty day simple moving average of $76.20 and a two-hundred day simple moving average of $73.65.

Insmed (NASDAQ:INSM - Get Free Report) last announced its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($0.15). The business had revenue of $104.44 million during the quarter, compared to analyst estimates of $102.31 million. Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. As a group, research analysts expect that Insmed Incorporated will post -4.56 EPS for the current fiscal year.

Insider Buying and Selling at Insmed

In other news, CEO William Lewis sold 18,750 shares of the business's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $81.03, for a total value of $1,519,312.50. Following the completion of the transaction, the chief executive officer now owns 334,186 shares of the company's stock, valued at $27,079,091.58. The trade was a 5.31 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Sara Bonstein sold 28,390 shares of the firm's stock in a transaction dated Thursday, February 6th. The stock was sold at an average price of $80.90, for a total value of $2,296,751.00. Following the sale, the chief financial officer now directly owns 155,506 shares in the company, valued at approximately $12,580,435.40. This represents a 15.44 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 499,613 shares of company stock valued at $39,569,355. 4.60% of the stock is currently owned by company insiders.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.